>latest-news

Silo Pharma Enters Digital Asset Market With AI-Powered Treasury Strategy Led By Corwin Yu

Silo Pharma enters crypto with a treasury plan targeting BTC, ETH, and SOL, led by fintech expert Corwin Yu.

Breaking News

  • Aug 07, 2025

  • Vaibhavi M.

Silo Pharma Enters Digital Asset Market With AI-Powered Treasury Strategy Led By Corwin Yu

Silo Pharma has announced the launch of a cryptocurrency treasury strategy focused on major digital assets, including Bitcoin, Ethereum, and Solana. The company plans to make opportunistic investments, utilize staking to generate yield, and pursue a balance between capital preservation and token appreciation. Expansion of the strategy will depend on capital availability and broader market conditions.

“With the recent rise of successful cryptocurrency treasury allocations and increasing capital inflows to digital assets, we believe there is an opportunity to potentially create and unlock long-term value for Silo’s stockholders, starting now. We believe that we are fortunate to appoint Corwin Yu as our lead strategic advisor and head of a newly formed three-member advisory board overseeing our crypto treasury strategy, with 2 other members to be appointed in the future,” said Silo CEO Eric Weisblum. 

To lead this initiative, Silo has appointed Corwin Yu, a seasoned fintech executive and crypto trading pioneer, as the first member of its newly formed Crypto Advisory Board. Yu brings over two decades of experience in institutional finance and crypto infrastructure, including leadership roles at TSImagine, MARKTS, and firms such as PIMCO and Credit Suisse. He is known for building scalable, secure platforms and managing cross-asset and digital trading strategies.

“Alongside our launching of a digital asset treasury strategy, we remain deeply committed to our core biopharmaceutical enterprise focused on innovative therapeutics for underserved conditions,” Mr. Weisblum continued. “Our lead asset, PTSD drug SPC-15, is completing final studies before submitting an FDA investigational new drug (IND) application, and if such IND is approved we would look to commence a first-in-human Phase 1 clinical trial.”

Supporting the crypto strategy, Silo has also acquired AI-powered market intelligence technology to enable real-time decision-making. With this, the company aims to enhance its strategic responsiveness in digital asset management and drive informed execution. This move marks a notable expansion of Silo’s capital management approach into the emerging digital finance space.

Ad
Advertisement